This research will determine the efficacy of intramuscular (IM) recombinant human fibroblast interferon (rIFN-B) administered for exacerbating multiple sclerosis (MS) under randomized, double-blinded, placebo controlled conditions. Our previous double-blinded study demonstrated that intrathecal (IT) natural IFN-B was effective in reducing MS exacerbations. The IT route of administration for that study was dictated by the belief that systemic IFN- B did not cross the blood-brain barrier (BBB). However, there is new evidence indicating that systemic IFN-B does cross the BBB which compels assessment of systemically administered interferon in MS. This multicentered study will include 288 patients with active exacerbating MS who will be randomly assigned to receive IM injections of rIFN-B or placebo. Treatments will be performed weekly for 104 weeks. The primary measure of efficacy will be the intergroup difference in the time to progression in disability as measured by the Kurtzke Expanded Disability Scale of at least 1.0 units which persists for six months. Additionally, a number of other important parameters of MS disease activity and patient functional status will be analyzed as secondary outcome measures. Our recently completed Pilot Study determined that 6 x 106 IU administered IM weekly was the ideal dose and schedule of rIFN-B which significantly induced measures of interferon biologic activity under double-blinded conditions. Further at this dosage of rIFN-B, acetaminophen was effective in facilitating blinding, thus obviating the need for previously used indomethacin which had potentially confounding immunologic effects. If the results of this study are positive, then rFIN-B may be widely employed in the future as a practicle clinical too in the treatment of MS.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS026321-04
Application #
2265883
Study Section
Special Emphasis Panel (SRC (09))
Project Start
1990-06-01
Project End
1995-05-31
Budget Start
1993-06-01
Budget End
1995-05-31
Support Year
4
Fiscal Year
1993
Total Cost
Indirect Cost
Name
State University of New York at Buffalo
Department
Biology
Type
Schools of Arts and Sciences
DUNS #
038633251
City
Buffalo
State
NY
Country
United States
Zip Code
14260
Fisher, E; Nakamura, K; Lee, J-C et al. (2016) Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis. Mult Scler 22:668-76
Bermel, Robert A; You, Xiaojun; Foulds, Pamela et al. (2013) Predictors of long-term outcome in multiple sclerosis patients treated with interferon ýý. Ann Neurol 73:95-103
Hyland, Megan; Rudick, Richard A (2011) Challenges to clinical trials in multiple sclerosis: outcome measures in the era of disease-modifying drugs. Curr Opin Neurol 24:255-61
Jacobs, L; Rudick, R; Simon, J (2000) Extended observations on MS patients treated with IM interferon-beta1a (Avonex): implications for modern MS trials and therapeutics. J Neuroimmunol 107:167-73
Rudick, R A; Cookfair, D L; Simonian, N A et al. (1999) Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. J Neuroimmunol 93:8-14
Rudick, R A; Ransohoff, R M; Lee, J C et al. (1998) In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology 50:1294-300
Jacobs, L; Johnson, K P (1994) A brief history of the use of interferons as treatment of multiple sclerosis. Arch Neurol 51:1245-52
Rudick, R A; Carpenter, C S; Cookfair, D L et al. (1993) In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta. Neurology 43:2080-7
Goodkin, D E; Cookfair, D; Wende, K et al. (1992) Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group. Neurology 42:859-63